Affecting as many as 46-77% of cancer patients, taste alterations known as dysgeusia, is considered one of the most disturbing side effects experienced by cancer patients receiving chemotherapy treatment. Miracle berries are a food that some people have found help them with this taste alteration.
Researchers at NICM Health Research Institute are conducting a seven day study to investigate the effectiveness of miracle berries for dysgeusia experienced by cancer patients undergoing, or have undergone chemotherapy. The study will test whether the miracle berries help improve taste, poor appetite and nausea, as well as quality of life.
Who can join?
- Men or women aged 18-65 years.
- Cancer patients who:
- Are undergoing chemotherapy or have completed chemotherapy within the last 12 months.
- Screen positive to screening questions confirming current experience of dysgeusia.
- Do not have cancer of the head or neck.
- Are not allergic to berries.
- Do not have serious psychological conditions.
After assessment and consent, participants will be asked to:
- Travel to NICM Health Research Institute at the start and completion of the study to complete a questionnaire and undergo a taste sensation test.
- Over seven days, take one miracle berry 15 minutes before each main meal.
What are the benefits of participating?
- Miracle berries may help with the dysgeusia, poor appetite or nausea.
- Once you have completed your second and final clinic visit, you will be reimbursed for your travel expenses by way of a $50 gift voucher.
- May improve quality of life.
- May improve future treatment of taste alteration in people who are undoing or have undergone chemotherapy.
For more information, please contact:
NICM Study Research Assistant
p. 0490 140 187
Interested in participating in this study?
Please complete and submit the following information.
Required fields are marked with an asterisk (*).
For further information or questions please contact Atekah Albrehee, NICM Study Research Assistant via email email@example.com.
Human Research Ethics Committee Approval: This clinical trial has been approved by Western Sydney University Human Research Ethics Committee (Approval Number: H12946).
The study is supported by NICM Health Research Institute, Western Sydney University.
NICM Chief Investigator: Dr Suzanne Grant